Lilly buying spree surpasses $32B with Calytrix Bio deal
FROM THE WIRE · FINANCE.YAHOO.COM
Bloomberg's Madison Muller joins Dani Burger on "Bloomberg Deals." Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker's $32 billion wave of acquisitions in 2026 as it builds out its cancer and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralLilly's acquisitions in oncology and immunology are relevant to the pharma sector and the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Eli Lilly agreed to buy Calytrix Bio in a deal worth up to $1.5 billion.
- 02The deal adds to a $32 billion wave of acquisitions in 2026.
- 03The company is building out its cancer and immunology businesses.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets